BioRestorative Therapies 

0
38
+€0.00+0% 00:00 今天

統計

當日最高
-
當日最低
-
52週高點
-
52週低點
-
成交量
-
平均成交量
-
市值
0
本益比
-
股息殖利率
-
股息
-

財報

14May預期
Q1 2026
-3.43
-3.1
-2.76
-2.43
預期EPS
-3.4292
實際EPS
不適用

競爭對手

此清單為基於近期市場事件的分析。並非投資建議。

關於

BioRestorative Therapies Inc is engaged in developing therapeutic products using cell and tissue protocols, involving adult stem cells. The company is pursuing its Disc/Spine Program with initial investigational therapeutic product being called BRTX-100 in the treatment of chronic cervical discogenic pain. The technology is an stem cell injection procedure that may offer relief from lower back pain, buttock and leg pain, and numbness and tingling in the leg and foot. It is also developing ThermoStem Program, a pre-clinical program which involves the use of brown adipose (fat) in connection with the cell-based treatment of type 2 diabetes and obesity as well as hypertension, other metabolic disorders and cardiac deficiencies.
Show more...
執行長
Katharyn Field
員工
14
國家
美國
ISIN
US0906557055
WKN
000A42DVS

上市

0 Comments

分享你的想法

FAQ

BioRestorative Therapies 的股票代號是什麼?
根據交易所不同,股票代號可能會有所差異。例如,在 Frankfurt Exchange 交易所,BioRestorative Therapies 的股票以代號 9OF0.F 進行交易。
BioRestorative Therapies 有多少名員工?
截至 September 09, 2026,公司共有 14 名員工。
BioRestorative Therapies 位於哪個產業?
BioRestorative Therapies從事於Health & Wellness產業。
BioRestorative Therapies 何時完成拆股?
BioRestorative Therapies 最近沒有進行任何拆股。
BioRestorative Therapies 的總部在哪裡?
BioRestorative Therapies 的總部位於 美國 的 MELVILLE。